Drugs / HBAI20
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02540538 | Sep 2015 → Jul 2016 | hepatitis B virus infection | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03415672 | Oct 2017 → Jan 2019 | hepatitis B virus infection | Maastricht University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBAI20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02540538 ↗ |
| Modality | Vaccine | “This new adjuvant AI20, containing 20 μg recombinant human IL-2 attached to 20 μg aluminium hydroxide, was added to HBVaxPro©-10 μg (HBAI20).” PMID 29660190 ↗ May 2018 |
| Route | Intramuscular | “The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle” NCT03415672 ↗ |